The AFB Drug Susceptibility Panel 1st Line (4 Drugs – HREZ) evaluates the response of Mycobacterium tuberculosis to the primary anti-TB drugs: Isoniazid (H), Rifampicin (R), Ethambutol (E), and Pyrazinamide (Z). Metropolis Healthcare performs this test on pure culture isolates to deliver accurate, clinically actionable resistance profiles for effective TB treatment planning.
Price:
Rs. 6,150.00
Sample Type: Serum
Fasting Not Requierd
Frequently Asked Questions (FAQ's):
What does the AFB 1st Line Drug Susceptibility Panel at Metropolis Healthcare include?
It assesses susceptibility to the four key first-line anti-tubercular drugs: H, R, E, and Z.
How does Metropolis Healthcare perform this drug resistance test?
Pure culture isolates are tested using validated culture-based DST techniques under strict biosafety and quality standards.
Who should take this first-line DST test at Metropolis Healthcare?
Patients with confirmed TB, suspected drug resistance, prior treatment failure, or relapse should undergo this test.
Why are the four first-line drugs (HREZ) important?
These form the backbone of standard TB therapy, and resistance affects treatment success and regimen selection.
How do the results help in treatment planning?
They guide physicians in identifying effective drugs and adjusting treatment if resistance to H, R, E, or Z is detected.
Is any patient preparation needed for this test?
No patient preparation is required; the referring lab must provide a confirmed pure culture isolate.
How long does Metropolis Healthcare take to provide results?
As this is a culture-based test, results typically require several weeks depending on organism growth.
Is this test useful for detecting MDR-TB?
Yes. Resistance to both isoniazid and rifampicin identified at Metropolis Healthcare strongly indicates multidrug-resistant TB (MDR-TB)